Literature DB >> 12076276

Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas.

Ro Ra Oh1, Jik Young Park, Jong Heun Lee, Min Sun Shin, Hong Sug Kim, Sang Kyu Lee, Young Sil Kim, Sug Hyung Lee, Sie Nae Lee, Young Mok Yang, Nam Jin Yoo, Jung Young Lee, Won Sang Park.   

Abstract

We analyzed the genetic alterations of VHL, HGF/SF, and Met genes and the expression pattern of HGF/SF and Met protein in 26 renal cell carcinomas (RCCs). We found five mutations of the VHL gene and frequent LOH (50%) only in non-papillary clear cell RCC. We found six cases in which the CpG island of VHL was methylated. In addition, one missense mutation of the HGF/SF gene was detected in clear cell RCC. HGF/SF and Met protein were expressed in 84.6% and 80.7% of RCCs, respectively. All of the cases with the genetic alterations of VHL or HGF/SF demonstrated strong expression of HGF/SF and Met protein in RCC cells. Statistically, genetic alterations of VHL and HGF/SF were significantly correlated with HGF/SF and Met expression (Fisher's exact test, p=0.022 and p=0.0070). Thus, these results strongly suggest that the expression of HGF/SF and Met protein is closely associated with the genetic alterations of VHL and HGF/SF in primary RCCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076276     DOI: 10.1034/j.1600-0463.2002.100305.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  14 in total

1.  Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas.

Authors:  Shuigen Zhou; Longxin Wang; Guimei Li; Zhengyu Zhang; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.

Authors:  G T Gibney; S A Aziz; R L Camp; P Conrad; B E Schwartz; C R Chen; W K Kelly; H M Kluger
Journal:  Ann Oncol       Date:  2012-09-28       Impact factor: 32.976

3.  Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.

Authors:  Alison C Young; Rachel A Craven; Dena Cohen; Claire Taylor; Christopher Booth; Patricia Harnden; David A Cairns; Dewi Astuti; Walter Gregory; Eamonn R Maher; Margaret A Knowles; Adrian Joyce; Peter J Selby; Rosamonde E Banks
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

4.  Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.

Authors:  Eric Ciamporcero; Kiersten Marie Miles; Remi Adelaiye; Swathi Ramakrishnan; Li Shen; ShengYu Ku; Stefania Pizzimenti; Barbara Sennino; Giuseppina Barrera; Roberto Pili
Journal:  Mol Cancer Ther       Date:  2014-11-07       Impact factor: 6.261

Review 5.  Linking the history of radiation biology to the hallmarks of cancer.

Authors:  Mary-Keara Boss; Robert Bristow; Mark W Dewhirst
Journal:  Radiat Res       Date:  2014-05-08       Impact factor: 2.841

Review 6.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

7.  Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma.

Authors:  May Elbanna; Ashley R Orillion; Nur P Damayanti; Remi Adelaiye-Ogala; Li Shen; Kiersten Marie Miles; Sreenivasulu Chintala; Eric Ciamporcero; Swathi Ramakrishnan; Sheng-Yu Ku; Karen Rex; Sean Caenepeel; Angela Coxon; Roberto Pili
Journal:  Mol Cancer Ther       Date:  2019-10-03       Impact factor: 6.261

8.  Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.

Authors:  R M Gemmill; M Zhou; L Costa; C Korch; R M Bukowski; H A Drabkin
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

Review 9.  Met in urological cancers.

Authors:  Yasuyoshi Miyata; Akihiro Asai; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Yasushi Mochizuki; Hideki Sakai
Journal:  Cancers (Basel)       Date:  2014-12-16       Impact factor: 6.639

10.  Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.

Authors:  Da Eun Jeong; Hye Jin Jin Song; Sharon Lim; Se Jeong Jeong Lee; Joung Eun Lim; Do-Hyun Nam; Kyeung Min Joo; Byong Chang Jeong; Seong Soo Jeon; Han Yong Choi; Hye Won Lee
Journal:  Oncotarget       Date:  2015-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.